← All Madrigal Pharmaceuticals, INC filings

Madrigal Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
MDGL
Madrigal Pharmaceuticals, INC
10-K: Madrigal Pharmaceuticals Reports Strong Rezdiffra Sales, Expands MASH Pipeline
Madrigal Pharmaceuticals achieved significant product revenue of $958.4 million in 2025 from its MASH drug Rezdiffra, while expanding its pipeline with new therapeutic candidates.
NASDAQ
MDGL
Madrigal Pharmaceuticals, INC
10-K: Madrigal Pharmaceuticals Reports Transformational Year, Fueled by Rezdiffra Approval and Strategic Growth Initiatives
Madrigal Pharmaceuticals highlights a transformational year marked by Rezdiffra's FDA approval, a successful public offering, and strategic expansion into Europe.
NASDAQ
MDGL
Madrigal Pharmaceuticals, INC
10-K: Madrigal Pharmaceuticals Releases 10-K Filing, Highlights Progress on NASH Treatment
Madrigal Pharmaceuticals' 10-K filing details the company's financial status and progress in developing resmetirom for NASH treatment, including FDA review and clinical trial results.